Home › Trials › NCT06994169

Real-world outcomes with glofitamab for large B-cell lymphoma

Glofitamab in Real Life

The Lymphoma Academic Research Organisation · NCT06994169

This project looks at how well glofitamab works and how safe it is for adults in France with relapsed or refractory large B‑cell lymphoma who were treated through the expanded access program.

Quick facts

Study typeObservational
Enrollment250 (estimated)
Ages18 Years and up
SexAll
SponsorThe Lymphoma Academic Research Organisation (other)
Drugs / interventionsGlofitamab, Obinutuzumab, CAR-T
Locations30 sites (Argenteuil and 29 other locations)
Trial IDNCT06994169 on ClinicalTrials.gov

What this trial studies

This is a retrospective observational analysis of over 300 adults treated with glofitamab in the French expanded-access program, with an expected median follow-up of more than nine months. The project will summarize real-world efficacy and safety outcomes across participating centers. Special attention is given to patients previously treated with CAR‑T therapy to confirm reported complete response rates and to explore optimal timing of glofitamab initiation. Included patients received obinutuzumab pretreatment and at least one glofitamab infusion and did not object to use of their data.

Who should consider this trial

Good fit: Adult patients enrolled in the French glofitamab expanded-access program before November 1, 2024 who received obinutuzumab pretreatment and at least one glofitamab infusion and who did not oppose data collection.

Not a fit: Patients not treated in the French EAP, pediatric patients, or those who did not receive obinutuzumab pretreatment or any glofitamab infusion are unlikely to be represented and therefore may not benefit from the study findings.

Why it matters

Potential benefit: If successful, the findings could help clinicians better predict which patients benefit from glofitamab and inform optimal timing of treatment in relapsed/refractory large B‑cell lymphoma.

How similar studies have performed: Previous clinical trials and expanded-access reports have shown promising response rates for glofitamab, including reported CRR around 35–39% in CAR‑T‑exposed patients, but large real‑world cohorts are still limited.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* patient enrolled in the French Glofitamab EAP for R/R DLBCL before 2024 November 1st, 2024
* patient who received at least Obinutuzumab pretreatment and one infusion of Glofitamab
* adult patient
* patient who is informed of the study and who did not oppose to their data collection

Exclusion Criteria:

* none

Where this trial is running

Argenteuil and 29 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Large B-cell Lymphoma, CAR-T, Glofitamab

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.